The present invention relates to the treatment of cardiovascular disease, more particularly to the treatment of subjects suffering from or at risk of suffering from atherosclerotic cardiovascular disease that are hypo-responsive to HIS treatment. The present inventors have found that HIS hypo-responders show remarkable improvements in their blood lipid profiles when their statin therapy is combined with treatment with the CETP inhibitor obicetrapib. In a general aspect, the present invention thus provides methods of treating subjects that are hypo-responsive to high intensity statin (HIS) therapy, said method comprising the administration of a composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.

The present invention relates to the treatment of cardiovascular disease, more particularly to the treatment of subjects suffering from or at risk of suffering from atherosclerotic cardiovascular disease that are hypo-responsive to HIS treatment. The present inventors have found that HIS hypo-responders show remarkable improvements in their blood lipid profiles when their statin therapy is combined with treatment with the CETP inhibitor obicetrapib. In a general aspect, the present invention thus provides methods of treating subjects that are hypo-responsive to high intensity statin (HIS) therapy, said method comprising the administration of a composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.

The present invention relates to the treatment of cardiovascular disease, more particularly to the treatment of subjects suffering from or at risk of suffering from atherosclerotic cardiovascular disease that are hypo-responsive to HIS treatment. The present inventors have found that HIS hypo-responders show remarkable improvements in their blood lipid profiles when their statin therapy is combined with treatment with the CETP inhibitor obicetrapib. In a general aspect, the present invention thus provides methods of treating subjects that are hypo-responsive to high intensity statin (HIS) therapy, said method comprising the administration of a composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

This invention relates to compounds of Formula (I):

##STR00001##

and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

This invention relates to compounds of Formula (I):

##STR00001##

and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection. The compositions may be administered intact, or may be crushed prior to administration.